Leukemia Research Reports (Jan 2024)

Management of patients with concurrent clonal plasma cell and myeloid disorders: A single center descriptive case series

  • Michael J. Hochman,
  • Gloria F. Gerber,
  • Philip H. Imus,
  • Syed Abbas Ali,
  • Amy E. DeZern

Journal volume & issue
Vol. 22
p. 100469

Abstract

Read online

Both clonal plasma cell and myeloid disorders occur more frequently with age. Patients with concurrent clonal plasma cell and myeloid disorders (CPCMD) can present clinical and therapeutic challenges. In this single-institution cohort of patients with CPCMD (n = 18), we abstracted clinically relevant themes. A majority of patients (12/18) were treated with clone-directed therapies and three received treatment targeting both clones. Treatment of clones with targetable genetic lesions or those causing end-organ complications should be prioritized. Simultaneous treatment of both clones can be safe but is best done in a stepwise manner. Further study of patients with dual clonal processes is warranted.

Keywords